These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 25412509)
1. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations. Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509 [TBL] [Abstract][Full Text] [Related]
2. Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition. Dixit SM; Ahsan M; Senapati S Biochemistry; 2019 Sep; 58(36):3789-3801. PubMed ID: 31418269 [TBL] [Abstract][Full Text] [Related]
3. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069 [TBL] [Abstract][Full Text] [Related]
4. Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback. Yang Z; Cao Y; Hao D; Yuan X; Zhang L; Zhang S J Biomol Struct Dyn; 2018 Aug; 36(10):2567-2580. PubMed ID: 28777919 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012 [TBL] [Abstract][Full Text] [Related]
6. Anacetrapib as a potential cardioprotective strategy. Di Bartolo BA; Nicholls SJ Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647 [TBL] [Abstract][Full Text] [Related]
7. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106 [TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Shinkai H Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899 [TBL] [Abstract][Full Text] [Related]
9. Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations. Koivuniemi A; Vuorela T; Kovanen PT; Vattulainen I; Hyvönen MT PLoS Comput Biol; 2012 Jan; 8(1):e1002299. PubMed ID: 22253581 [TBL] [Abstract][Full Text] [Related]
10. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? Page MM; Hooper AJ; Burnett JR Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232 [TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Mabuchi H; Nohara A; Inazu A Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905 [TBL] [Abstract][Full Text] [Related]
12. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors. Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1606-1617. PubMed ID: 28911944 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors. Chirasani VR; Sankar R; Senapati S J Phys Chem B; 2016 Aug; 120(33):8254-63. PubMed ID: 27111423 [TBL] [Abstract][Full Text] [Related]
14. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406 [TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344 [TBL] [Abstract][Full Text] [Related]
16. Anacetrapib, a cholesteryl ester transfer protein inhibitor. Hooper AJ; Burnett JR Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425 [TBL] [Abstract][Full Text] [Related]
17. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P; J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362 [TBL] [Abstract][Full Text] [Related]
18. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib. Miyares MA; Davis K Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305 [TBL] [Abstract][Full Text] [Related]
19. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. Roddy TP; McLaren DG; Chen Y; Xie D; Dunn K; Kulick A; Szeto D; Forrest G; Albanese K; Donnelly M; Gai C; Gewain A; Lederman H; Jensen KK; Ai X; Vachal P; Akinsanya KO; Cleary MA; Previs SF; Dansky HM; Johns DG Eur J Pharmacol; 2014 Oct; 740():410-6. PubMed ID: 24769414 [TBL] [Abstract][Full Text] [Related]
20. Anacetrapib: a potential new therapy for dyslipidemia. Robinson LB; Frishman WH Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]